Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastati...

Comment: Veliparib with carboplatin and paclitaxel in advanced gBRCA-positive breast cancersПодробнее

BROCADE3: veliparib with carboplatin/paclitaxel in HER2-/BRCA+ advanced breast cancerПодробнее

Neelima Denduluri, MD -- Treatment of Triple Negative Breast CancerПодробнее

Rationale for Chemotherapy Plus Veliparib in Frontline Treatment of Ovarian CancersПодробнее

Combination Veliparib and Chemotherapy in Ovarian CancerПодробнее

Is carboplatin an effective addition in the treatment of breast cancer?Подробнее

PARP inhibitory velaparib trialled in BRCA1/2 breast cancerПодробнее

Combination of Veliparib and Chemotherapy in BRCA-Positive Breast CancerПодробнее

Veliparib misses PFS endpoint, advances to phase III trialПодробнее

NRG-GY026Подробнее

ADAPT: de-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel in HR-/HER2+ eBCПодробнее

ARMANI: Ramucirumab Plus Paclitaxel as Switch Maintenance for Advanced HER2-Negative Gastric CancerПодробнее

ENGOT-EN1: carboplatin plus paclitaxel plus nintedanib for endometrial cancerПодробнее

ASCO 2020 - Heather Han, MD - Abstract 1091Подробнее

Study of Nab-Paclitaxel with Pembrolizumab for Patients with HR+/HER2- Breast CancerПодробнее

Novel Therapeutics for Breast Cancer: HER2+ and Triple Negative Disease; New Pathways, TargetsПодробнее

Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2-negative advance...Подробнее

A Phase III Study of Paclitaxel With Everolimus in Gastric CancerПодробнее

Rebastinib plus paclitaxel shows encouraging anti-tumor activity in endometrial cancerПодробнее